Fig 1: Immunoblot analysis of the levels of the proteins p-MED1 and MED1 expressed in BT-474 tumor xenografts.Three samples from each group were randomly selected. Similar results were obtained after two experimental repeats. Thus, representative bands from a single experiment are shown here. Trastuzumab and fulvestrant as single agents decreased levels of the protein p-MED1 (P<0.05) and the combination resulted in lower expression levels when compared with fulvestrant alone (P = 0.039). In addition, total protein levels of MED1 increased in the combination group compared with the vehicle-treated group (P = 0.017).
Fig 2: Immunoblot analysis of the levels of the proteins p-MED1 and MED1 expressed in ZR-75-1 tumor xenografts.Three samples from each group were randomly selected. Similar results were obtained after two experimental repeats. Thus, representative bands from a single experiment are shown here. Trastuzumab and fulvestrant either as single agents or in combination decreased levels of the protein p-MED1 (P<0.05) and increased levels of MED1 total protein (P<0.05). However, no significant differences were observed between combination groups and individually treated groups (P>0.05).
Supplier Page from Abcam for Anti-TRAP220/MED1 (phospho T1457) antibody [EPR13269]